Celldex Therapeutics, Inc. (NASDAQ:CLDX) Short Interest Update

Celldex Therapeutics, Inc. (NASDAQ:CLDXGet Free Report) was the recipient of a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 5,900,000 shares, a drop of 8.0% from the February 29th total of 6,410,000 shares. Based on an average daily volume of 927,100 shares, the days-to-cover ratio is currently 6.4 days.

Celldex Therapeutics Price Performance

Shares of Celldex Therapeutics stock traded down $0.48 on Tuesday, reaching $41.16. 1,316,269 shares of the company were exchanged, compared to its average volume of 958,974. Celldex Therapeutics has a 1-year low of $22.11 and a 1-year high of $53.18. The company has a market cap of $2.30 billion, a P/E ratio of -14.14 and a beta of 1.50. The stock’s 50 day moving average price is $41.33 and its 200-day moving average price is $34.76.

Celldex Therapeutics (NASDAQ:CLDXGet Free Report) last announced its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.19. Celldex Therapeutics had a negative return on equity of 41.06% and a negative net margin of 2,054.46%. The business had revenue of $4.13 million during the quarter, compared to the consensus estimate of $1.20 million. On average, research analysts predict that Celldex Therapeutics will post -2.93 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Celldex Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in CLDX. MetLife Investment Management LLC boosted its holdings in Celldex Therapeutics by 1.5% in the second quarter. MetLife Investment Management LLC now owns 24,073 shares of the biopharmaceutical company’s stock valued at $817,000 after purchasing an additional 349 shares in the last quarter. Legal & General Group Plc boosted its holdings in Celldex Therapeutics by 2.1% in the fourth quarter. Legal & General Group Plc now owns 17,215 shares of the biopharmaceutical company’s stock valued at $767,000 after purchasing an additional 360 shares in the last quarter. Silverarc Capital Management LLC boosted its holdings in Celldex Therapeutics by 0.9% in the first quarter. Silverarc Capital Management LLC now owns 45,538 shares of the biopharmaceutical company’s stock valued at $256,000 after purchasing an additional 406 shares in the last quarter. Nuveen Asset Management LLC boosted its holdings in Celldex Therapeutics by 0.3% in the second quarter. Nuveen Asset Management LLC now owns 120,968 shares of the biopharmaceutical company’s stock valued at $4,104,000 after purchasing an additional 420 shares in the last quarter. Finally, First Trust Advisors LP boosted its holdings in Celldex Therapeutics by 4.4% in the third quarter. First Trust Advisors LP now owns 10,399 shares of the biopharmaceutical company’s stock valued at $292,000 after purchasing an additional 440 shares in the last quarter.

Analyst Ratings Changes

Several equities analysts have weighed in on CLDX shares. Guggenheim lifted their target price on Celldex Therapeutics from $72.00 to $90.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. TD Cowen started coverage on Celldex Therapeutics in a research report on Wednesday, December 20th. They issued an “outperform” rating for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research report on Friday, March 22nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $66.00.

Check Out Our Latest Report on CLDX

Celldex Therapeutics Company Profile

(Get Free Report)

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

Featured Articles

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.